Page 154 - LAPORAN TAHUNAN HOSPITAL SULTANAH AMINAH 2022

10 NMRR -19- Dr Choon Siew Dermatology Effisayil 2: 2:Multi-center, ran- 1368-0027 Ongoing
-3561-51836 Eng domized, parallel group, double
blind, placebo controlled, Phase
IIb dose-finding study to eval-
uate efficacy and safety of BI
655130 (Spesolimab) compared
to placebo in preventing gener-
alized pustular psoriasis (GPP)
flares in patients with history of
GPP

11 NMRR-20-1795- Dr Azizan Sharif Medical A Phase II Study of The Hepci- PTG-300-008 Ongoing
56077 din Mimetic PTG-300 in Patients
with Polycythemia Vera and
Elevated Hematocrit

12 NMRR-20-794- Dr Lim Soo Min Medical A Phase 2 Study to Evaluate IMR-BTL-201 Ongoing
52788 the Safety and Tolerability of
IMR-687 in Subjects with Beta
Thalassemia
13 NMRR-21-1817- Dr Choon Siew Dermatology A Multicenter Registry of Pa- ANB019-401 Ongoing
61031 Eng tients with Generalized Pustu-
lar Psoriasis or Palmoplantar
Pustulosis

14 NMRR-20-996- Dr Choon Siew Dermatology A Multicenter, Double-blind, CAIN457M2301E1 / Ongoing
54540 Eng Randomized Withdrawal ex- SUNRISE EXT
tension study of subcutaneous
secukinumab to demonstrate
long-term efficacy, safety and
tolerability in subjects with
moderate to severe hidradenitis
suppurativa (HS)

15 NMRR-21-1903- Dr Choon Siew Dermatology Study for Efficacy and Safety of ANB019-301 Recruiting
61142 Eng Imsidolimab (ANB019) for Gen-
eralized Pustular Psoriasis

16 NMRR-21-1918- Dr Choon Siew Dermatology A Phase 3, Long-Term Extension ANB019-302 Recruiting
61166 Eng Study to Evaluate the Safety
and Efficacy of Imsidolimab
(ANB019) in the Treatment of
Adult Subjects with Generalized
Pustular Psoriasis

150